CN101868459B - 用于治疗糖尿病的、作为葡糖激酶激活剂的吡啶-2-基-氨基-1,2,4-噻二唑衍生物 - Google Patents
用于治疗糖尿病的、作为葡糖激酶激活剂的吡啶-2-基-氨基-1,2,4-噻二唑衍生物 Download PDFInfo
- Publication number
- CN101868459B CN101868459B CN2008801169950A CN200880116995A CN101868459B CN 101868459 B CN101868459 B CN 101868459B CN 2008801169950 A CN2008801169950 A CN 2008801169950A CN 200880116995 A CN200880116995 A CN 200880116995A CN 101868459 B CN101868459 B CN 101868459B
- Authority
- CN
- China
- Prior art keywords
- mmol
- base
- reaction
- pyridine
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 COc1cc(S*)cnc1Nc1nc(*)n[s]1 Chemical compound COc1cc(S*)cnc1Nc1nc(*)n[s]1 0.000 description 5
- CZTDRPUNAAWGRW-UHFFFAOYSA-N CC(C)Oc1c(C#N)ncc(SC)c1 Chemical compound CC(C)Oc1c(C#N)ncc(SC)c1 CZTDRPUNAAWGRW-UHFFFAOYSA-N 0.000 description 1
- MLHZXCRKJPUDAB-UHFFFAOYSA-N CCOC(c1nc(SC)ccc1)=O Chemical compound CCOC(c1nc(SC)ccc1)=O MLHZXCRKJPUDAB-UHFFFAOYSA-N 0.000 description 1
- LTQHJHYEZIPXMH-QGZVFWFLSA-N CCc1ncccc1Oc1cc(CC2=[I]C=CC=C2)cnc1Nc1nc([C@@H](CO)O)n[s]1 Chemical compound CCc1ncccc1Oc1cc(CC2=[I]C=CC=C2)cnc1Nc1nc([C@@H](CO)O)n[s]1 LTQHJHYEZIPXMH-QGZVFWFLSA-N 0.000 description 1
- YFIFJAISBYUTRU-UHFFFAOYSA-N COC(c(cc1)ncc1SC)=O Chemical compound COC(c(cc1)ncc1SC)=O YFIFJAISBYUTRU-UHFFFAOYSA-N 0.000 description 1
- WHGWKDHNFBVFIX-UHFFFAOYSA-N COC(c(cn1)cc(Cl)c1SC)=O Chemical compound COC(c(cn1)cc(Cl)c1SC)=O WHGWKDHNFBVFIX-UHFFFAOYSA-N 0.000 description 1
- GYHHXEYKBNHZFF-UHFFFAOYSA-N COc1c(C#N)ncc(SC)c1 Chemical compound COc1c(C#N)ncc(SC)c1 GYHHXEYKBNHZFF-UHFFFAOYSA-N 0.000 description 1
- URSYQIBBJXLQBW-UHFFFAOYSA-N COc1cc(OC)nc(SC)n1 Chemical compound COc1cc(OC)nc(SC)n1 URSYQIBBJXLQBW-UHFFFAOYSA-N 0.000 description 1
- GXCMABRXUXDVMW-UHFFFAOYSA-N COc1nc(SC)ncc1 Chemical compound COc1nc(SC)ncc1 GXCMABRXUXDVMW-UHFFFAOYSA-N 0.000 description 1
- AHDVEMLHVUWLHI-UHFFFAOYSA-N COc1nccc(SC)c1 Chemical compound COc1nccc(SC)c1 AHDVEMLHVUWLHI-UHFFFAOYSA-N 0.000 description 1
- COONHACHVMHEKN-UHFFFAOYSA-N CSc(cc1)ncc1C#N Chemical compound CSc(cc1)ncc1C#N COONHACHVMHEKN-UHFFFAOYSA-N 0.000 description 1
- OUJCEVZWCQMIPU-UHFFFAOYSA-N CSc(ncc(C(O)=O)c1)c1Cl Chemical compound CSc(ncc(C(O)=O)c1)c1Cl OUJCEVZWCQMIPU-UHFFFAOYSA-N 0.000 description 1
- KHIMMMAZSQUTMF-UHFFFAOYSA-N CSc1cc(C#N)ccn1 Chemical compound CSc1cc(C#N)ccn1 KHIMMMAZSQUTMF-UHFFFAOYSA-N 0.000 description 1
- ULSHUQURGMGRBX-UHFFFAOYSA-N CSc1ccc(C(F)(F)F)nc1 Chemical compound CSc1ccc(C(F)(F)F)nc1 ULSHUQURGMGRBX-UHFFFAOYSA-N 0.000 description 1
- CCXGNCREYVMEOL-UHFFFAOYSA-N CSc1ccnc(Cl)c1 Chemical compound CSc1ccnc(Cl)c1 CCXGNCREYVMEOL-UHFFFAOYSA-N 0.000 description 1
- LKIVEIAXFZBGMO-UHFFFAOYSA-N C[n]1c(SC)ncc1 Chemical compound C[n]1c(SC)ncc1 LKIVEIAXFZBGMO-UHFFFAOYSA-N 0.000 description 1
- XBLSDCLXSAHQJS-UHFFFAOYSA-N C[n]1c(SC)nnc1 Chemical compound C[n]1c(SC)nnc1 XBLSDCLXSAHQJS-UHFFFAOYSA-N 0.000 description 1
- BKPOKYNAGIKTMC-UHFFFAOYSA-N Cc(cc1)ncc1SC Chemical compound Cc(cc1)ncc1SC BKPOKYNAGIKTMC-UHFFFAOYSA-N 0.000 description 1
- ZIAWRTFLHBOWGH-UHFFFAOYSA-N Cc(nccc1)c1SC Chemical compound Cc(nccc1)c1SC ZIAWRTFLHBOWGH-UHFFFAOYSA-N 0.000 description 1
- UKHFJAHXZAMXLJ-CYBMUJFWSA-N Cc1ccccc1Oc1cc(SCCO)cnc1Nc1nc([C@@H](CO)O)n[s]1 Chemical compound Cc1ccccc1Oc1cc(SCCO)cnc1Nc1nc([C@@H](CO)O)n[s]1 UKHFJAHXZAMXLJ-CYBMUJFWSA-N 0.000 description 1
- PCOMIRCNMMNOAP-CQSZACIVSA-N Cc1ncccc1Oc1cc(Sc2ncccc2)cnc1Nc1nc([C@@H](CO)O)n[s]1 Chemical compound Cc1ncccc1Oc1cc(Sc2ncccc2)cnc1Nc1nc([C@@H](CO)O)n[s]1 PCOMIRCNMMNOAP-CQSZACIVSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97422507P | 2007-09-21 | 2007-09-21 | |
| US60/974,225 | 2007-09-21 | ||
| US60/974225 | 2007-09-21 | ||
| PCT/US2008/076401 WO2009042435A1 (en) | 2007-09-21 | 2008-09-15 | Pyridin-2 -yl-amino-i, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101868459A CN101868459A (zh) | 2010-10-20 |
| CN101868459B true CN101868459B (zh) | 2013-12-18 |
Family
ID=40250949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008801169950A Expired - Fee Related CN101868459B (zh) | 2007-09-21 | 2008-09-15 | 用于治疗糖尿病的、作为葡糖激酶激活剂的吡啶-2-基-氨基-1,2,4-噻二唑衍生物 |
Country Status (28)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2131656A4 (en) * | 2006-11-15 | 2011-12-07 | Forest Lab Holdings Ltd | phthalazine |
| EA019104B1 (ru) | 2007-09-21 | 2014-01-30 | Эррей Биофарма Инк. | Активаторы глюкокиназы |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| CA2800498C (en) | 2010-03-31 | 2021-11-16 | The Scripps Research Institute | Reprogramming cells |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| MX2013002208A (es) | 2010-08-23 | 2013-05-30 | Amgen Inc | Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. |
| KR20140051834A (ko) | 2011-03-09 | 2014-05-02 | 다이이찌 산쿄 가부시키가이샤 | 디피리딜아민 유도체 |
| WO2012138776A1 (en) | 2011-04-05 | 2012-10-11 | Amgen Inc. | Benzodioxepine and benzodioxine compounds that interact with glucokinase regulatory protein for the treatment of diabetes |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN104230892B (zh) * | 2011-11-09 | 2016-12-07 | 福建海西新药创制有限公司 | 一组提高激酶活性的化合物及其应用 |
| WO2013123444A1 (en) | 2012-02-17 | 2013-08-22 | Amgen Inc. | Sulfonyl compounds that interact with glucokinase regulatory protein |
| WO2013173382A1 (en) | 2012-05-15 | 2013-11-21 | Amgen Inc. | Benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein |
| EP2850057A4 (en) * | 2012-05-18 | 2016-01-27 | Amgen Inc | PROCESS FOR THE PREPARATION OF THIADIAZOLENE |
| US20150299182A1 (en) * | 2012-11-09 | 2015-10-22 | Amgen Inc. | Crystalline forms of (1s)-1-[5-(amino)-1,2,4-thiadiazol-3-yl]ethane-1,2-diol |
| WO2016059647A2 (en) * | 2014-10-13 | 2016-04-21 | SHRI CHHATRAPTI SHIVAJI COLLEGE Maharashtra, India) | Triaminotriazine picolinonitrile derivatives as potent reverse transcriptase inhibitor of hiv-1 |
| GB201714777D0 (en) | 2017-09-14 | 2017-11-01 | Univ London Queen Mary | Agent |
| BR112020008727A2 (pt) | 2017-10-30 | 2020-10-20 | Neuropore Therapies, Inc. | fenil sulfonil fenil triazol tionas substituídas e usos destas |
| BR112020024269A2 (pt) * | 2018-05-31 | 2021-02-23 | Hua Medicine (Shanghai) Ltd. | combinação farmacêutica, composição e formulação de combinação contendo ativador de glucoquinase e ativador de receptor ppar e métodos de preparação e usos dos mesmos |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1348370A (zh) * | 1999-04-15 | 2002-05-08 | 布里斯托尔-迈尔斯斯奎布公司 | 环状蛋白酪氨酸激酶抑制剂 |
| CN1390215A (zh) * | 1999-09-10 | 2003-01-08 | 麦克公司 | 酪氨酸激酶抑制剂 |
| WO2007026761A1 (ja) * | 2005-08-31 | 2007-03-08 | Astellas Pharma Inc. | チアゾール誘導体 |
| WO2007053345A1 (en) * | 2005-11-01 | 2007-05-10 | Array Biopharma Inc. | Glucokinase activators |
| WO2007117381A2 (en) * | 2006-03-24 | 2007-10-18 | Array Biopharma Inc. | 2 -aminopyridine analogs as glucokinase activators |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3983246A (en) | 1974-04-04 | 1976-09-28 | Fmc Corporation | N-(sulfonyloxy) benzimidoyl halides as bactericidal or fungicidal agents |
| DE2949913A1 (de) * | 1979-12-12 | 1981-06-25 | Basf Ag, 6700 Ludwigshafen | Azofarbstoffe |
| EP0300688A1 (en) | 1987-07-21 | 1989-01-25 | FISONS plc | Pyrrole derivatives, process for their preparation and pharmaceutical compositions containing them |
| JPH0228168A (ja) * | 1988-04-14 | 1990-01-30 | Sankyo Co Ltd | チアゾール誘導体 |
| WO1993017681A1 (en) | 1992-03-02 | 1993-09-16 | Abbott Laboratories | Angiotensin ii receptor antagonists |
| WO1993024442A1 (fr) | 1992-05-29 | 1993-12-09 | Yamanouchi Pharmaceutical Co., Ltd. | Medicament renfermant un derive d'acide benzoique, et nouveau derive d'acide benzoique |
| JP3056788B2 (ja) | 1994-06-24 | 2000-06-26 | ユーロ−セルティーク,エス.エイ. | ホスホジエステラーゼivの阻害化合物および阻害方法 |
| GB9908410D0 (en) * | 1999-04-13 | 1999-06-09 | Pfizer Ltd | Pyridines |
| US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| HRP20010795A2 (en) | 1999-04-28 | 2003-02-28 | Aventis Pharma Gmbh | Di-aryl acid derivatives as ppar receptor ligands |
| US6465467B1 (en) | 1999-05-21 | 2002-10-15 | Biovitrum Ab | Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases |
| CA2374898C (en) | 1999-05-21 | 2009-12-08 | Biovitrum Ab | Pyrazinyl-piperazine compounds, their use and preparation |
| JP4144978B2 (ja) | 1999-09-09 | 2008-09-03 | 富士フイルム株式会社 | 1,2,4−チアジアゾール誘導体の合成法 |
| CA2396693A1 (en) | 1999-12-28 | 2001-07-05 | Stephen T. Wrobleski | Cytokine, especially tnf-alpha, inhibitors |
| US6906067B2 (en) | 1999-12-28 | 2005-06-14 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-α expression |
| US20020065270A1 (en) | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
| US7345051B2 (en) | 2000-01-31 | 2008-03-18 | Genaera Corporation | Mucin synthesis inhibitors |
| DZ3398A1 (fr) | 2000-08-31 | 2002-03-07 | Pfizer Prod Inc | Derives pyrazole et leur utilisation comme inhibiteurs des proteines kinases |
| US20050209297A1 (en) | 2000-08-31 | 2005-09-22 | Pfizer Inc | Pyrazole derivatives |
| AU2002213467A1 (en) | 2000-10-11 | 2002-04-22 | Chemocentryx, Inc. | Modulation of ccr4 function |
| WO2002030357A2 (en) | 2000-10-11 | 2002-04-18 | Chemocentryx, Inc. | Compounds and methods for modulating ccr4 function |
| AU3950802A (en) | 2000-12-07 | 2002-06-18 | Cv Therapeutics Inc | Abca-1 elevating compounds |
| BR0116493A (pt) | 2000-12-21 | 2003-09-30 | Vertex Pharma | Compostos de pirazol úteis como inibidores de proteìna cinase |
| AU2002258400A1 (en) | 2001-02-16 | 2002-08-28 | Tularik Inc. | Methods of using pyrimidine-based antiviral agents |
| WO2002094264A1 (en) | 2001-05-23 | 2002-11-28 | Tularik Inc. | Ccr4 antagonists |
| CA2450934A1 (en) | 2001-06-19 | 2002-12-27 | Marco Dodier | Pyrimidine inhibitors of phosphodiesterase (pde) 7 |
| PE20030008A1 (es) | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
| ATE316088T1 (de) * | 2001-06-22 | 2006-02-15 | Merck & Co Inc | Tyrosin-kinase inhibitoren |
| EP1465900B1 (en) | 2002-01-10 | 2008-05-14 | Bayer HealthCare AG | Rho-kinase inhibitors |
| ATE511858T1 (de) | 2002-02-05 | 2011-06-15 | Astellas Pharma Inc | 2,4,6-triamino-1,3,5-triazin-derivat |
| US6846928B2 (en) | 2002-03-15 | 2005-01-25 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| AU2003225800A1 (en) | 2002-03-15 | 2003-09-29 | Hayley Binch | Azolylaminoazine as inhibitors of protein kinases |
| US20040009981A1 (en) | 2002-03-15 | 2004-01-15 | David Bebbington | Compositions useful as inhibitors of protein kinases |
| WO2003077921A1 (en) | 2002-03-15 | 2003-09-25 | Vertex Pharmaceuticals, Inc. | Azinylaminoazoles as inhibitors of protein kinases |
| MXPA04009541A (es) | 2002-03-29 | 2005-01-25 | Chiron Corp | Benzazoles sustituidos y uso de los mismos como inhibidores de cinasa raf. |
| US8299108B2 (en) | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
| AU2003227360A1 (en) * | 2002-04-25 | 2003-11-10 | Yamanouchi Pharmaceutical Co., Ltd. | Novel amide derivatives or salts thereof |
| AU2003249369A1 (en) | 2002-06-21 | 2004-01-06 | Cellular Genomics, Inc. | Certain amino-substituted monocycles as kinase modulators |
| CN1691944A (zh) | 2002-08-09 | 2005-11-02 | 阿斯利康(瑞典)有限公司 | 作为代谢型谷氨酸受体-5调节剂的噁二唑 |
| WO2004024159A1 (en) | 2002-09-10 | 2004-03-25 | Scios Inc. | INHIBITORS OF TFGβ |
| PL375021A1 (en) | 2002-10-03 | 2005-11-14 | Novartis Ag | Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes |
| EP1558609A4 (en) | 2002-10-30 | 2008-05-28 | Merck & Co Inc | KINASE INHIBITORS |
| CA2755297A1 (en) | 2003-02-10 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Processes for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a halo-heteroaryl and analogous processes |
| US20040248850A1 (en) | 2003-02-11 | 2004-12-09 | Kemia, Inc. | Compounds for the treatment of HIV infection |
| BRPI0407283A (pt) | 2003-02-13 | 2006-01-31 | Banyu Pharma Co Ltd | Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade |
| ATE396731T1 (de) | 2003-03-25 | 2008-06-15 | Vertex Pharma | Thiazole zur verwendung als inhibitoren von protein-kinasen |
| US7244763B2 (en) | 2003-04-17 | 2007-07-17 | Warner Lambert Company Llc | Compounds that modulate PPAR activity and methods of preparation |
| CN1845915A (zh) | 2003-09-02 | 2006-10-11 | 默克公司 | 作为亲代谢谷氨酸受体-5的调节剂的联吡啶胺和醚类化合物 |
| US7470712B2 (en) | 2004-01-21 | 2008-12-30 | Bristol-Myers Squibb Company | Amino-benzazoles as P2Y1 receptor inhibitors |
| WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| AR049418A1 (es) | 2004-02-27 | 2006-08-02 | Bayer Pharmaceuticals Corp | Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes. |
| KR20050091462A (ko) | 2004-03-12 | 2005-09-15 | 한국과학기술연구원 | 푸로피리미딘 화합물 및 이를 포함하는 ddr2 티로신키나아제 활성 저해제 |
| AU2005223610B2 (en) | 2004-03-23 | 2008-05-29 | Banyu Pharmaceutical Co., Ltd. | Substituted quinazoline or pyridopyrimidine derivative |
| US7781451B2 (en) | 2004-04-02 | 2010-08-24 | Novartis Ag | Thiazolopyridine derivatives, pharmaceut ical conditions containing them and methods of treating glucokinase mediated conditions |
| US7642354B2 (en) | 2004-04-13 | 2010-01-05 | Icagen, Inc. | Polycyclic pyrazines as potassium ion channel modulators |
| EP1737852A2 (en) | 2004-04-13 | 2007-01-03 | Icagen, Inc. | Polycyclic pyridines as potassium ion channel modulators |
| TW200606129A (en) * | 2004-07-26 | 2006-02-16 | Chugai Pharmaceutical Co Ltd | Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same |
| EP1844023A1 (en) | 2004-12-31 | 2007-10-17 | Sk Chemicals Co., Ltd. | Quinazoline derivatives for the treatment and prevention of diabetes and obesity |
| MX2007008434A (es) | 2005-01-19 | 2007-07-25 | Squibb Bristol Myers Co | Derivados de 2-fenoxi-n-(1,3,4-tiadizol-2il)piridin-3-amina y compuestos relacionados como inhibidores del receptor p2y1 para el tratamiento de trastornos tromboembolicos. |
| DE102005025161A1 (de) | 2005-06-01 | 2006-12-07 | Phenion Gmbh & Co. Kg | Derivate des Pyrimidins und Triazins und deren Verwendung |
| US7737151B2 (en) | 2005-08-18 | 2010-06-15 | Vertex Pharmaceuticals Incorporated | Pyrazine kinase inhibitors |
| WO2007038387A2 (en) | 2005-09-23 | 2007-04-05 | Yale University | Compounds and methods for the treatment of viruses and cancer |
| JP5249770B2 (ja) | 2005-11-03 | 2013-07-31 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼインヒビターとして有用なアミノピリジン |
| KR20070052207A (ko) | 2005-11-16 | 2007-05-21 | 주식회사 엘지생명과학 | 신규한 kdr 억제제 |
| ATE508126T1 (de) | 2005-11-16 | 2011-05-15 | Vertex Pharma | Als kinaseinhibitoren geeignete aminopyrimidine |
| JP5236499B2 (ja) * | 2006-01-27 | 2013-07-17 | アレイ バイオファーマ、インコーポレイテッド | グルコキナーゼ活性化剤 |
| WO2007131953A1 (en) | 2006-05-12 | 2007-11-22 | Ab Science | A new process for the synthesis of 2-aminoxazole compounds |
| WO2008024963A1 (en) | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Benzene, pyridine, and pyridazine derivatives |
| TW200825060A (en) | 2006-10-26 | 2008-06-16 | Astrazeneca Ab | Chemical compounds |
| JP5208123B2 (ja) | 2006-12-08 | 2013-06-12 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| US8431713B2 (en) | 2007-01-24 | 2013-04-30 | Array Biopharma, Inc. | 2-aminopyridine derivatives as glucokinase activators |
| JP5450108B2 (ja) * | 2007-03-23 | 2014-03-26 | アレイ バイオファーマ、インコーポレイテッド | グルコキナーゼ活性化剤としての2−アミノピリジン類似体 |
| ES2470341T3 (es) | 2007-04-05 | 2014-06-23 | Amgen, Inc | Moduladores de la aurora cinasa y método de uso |
| US20090012091A1 (en) | 2007-07-02 | 2009-01-08 | Kinagen, Inc. | Oximide derivatives and their therapeutical application |
| WO2009022171A1 (en) | 2007-08-13 | 2009-02-19 | Astrazeneca Ab | Pyridinyiioxy pyridines as alk5 inhibitors |
| EA019104B1 (ru) | 2007-09-21 | 2014-01-30 | Эррей Биофарма Инк. | Активаторы глюкокиназы |
| KR20100090250A (ko) | 2007-10-09 | 2010-08-13 | 메르크 파텐트 게엠베하 | 글루코키나제 활성체로서 유용한 피리딘 유도체 |
-
2008
- 2008-09-15 EA EA201000515A patent/EA019104B1/ru not_active IP Right Cessation
- 2008-09-15 UA UAA201004782A patent/UA101166C2/ru unknown
- 2008-09-15 ES ES13186328.4T patent/ES2569734T3/es active Active
- 2008-09-15 HR HRP20120814AT patent/HRP20120814T1/hr unknown
- 2008-09-15 BR BRPI0816881 patent/BRPI0816881A2/pt not_active IP Right Cessation
- 2008-09-15 NZ NZ583538A patent/NZ583538A/en not_active IP Right Cessation
- 2008-09-15 CN CN2008801169950A patent/CN101868459B/zh not_active Expired - Fee Related
- 2008-09-15 PL PL08834504T patent/PL2209778T3/pl unknown
- 2008-09-15 MX MX2010002772A patent/MX2010002772A/es active IP Right Grant
- 2008-09-15 JP JP2010525902A patent/JP5722037B2/ja not_active Expired - Fee Related
- 2008-09-15 AU AU2008305294A patent/AU2008305294B2/en not_active Ceased
- 2008-09-15 EP EP16160414.5A patent/EP3078662A1/en not_active Withdrawn
- 2008-09-15 DK DK08834504.6T patent/DK2209778T3/da active
- 2008-09-15 KR KR1020107008594A patent/KR101566042B1/ko not_active Expired - Fee Related
- 2008-09-15 US US12/678,995 patent/US8212045B2/en not_active Expired - Fee Related
- 2008-09-15 SI SI200830746T patent/SI2209778T1/sl unknown
- 2008-09-15 CA CA2699718A patent/CA2699718C/en not_active Expired - Fee Related
- 2008-09-15 EP EP13186328.4A patent/EP2727910B1/en not_active Not-in-force
- 2008-09-15 PT PT88345046T patent/PT2209778E/pt unknown
- 2008-09-15 MY MYPI2010001186A patent/MY180558A/en unknown
- 2008-09-15 EP EP12181665A patent/EP2573087A1/en not_active Withdrawn
- 2008-09-15 WO PCT/US2008/076401 patent/WO2009042435A1/en not_active Ceased
- 2008-09-15 ES ES08834504T patent/ES2393824T3/es active Active
- 2008-09-15 EP EP08834504A patent/EP2209778B1/en not_active Not-in-force
- 2008-09-19 TW TW097136197A patent/TWI423799B/zh not_active IP Right Cessation
- 2008-09-19 AR ARP080104095A patent/AR068628A1/es not_active Application Discontinuation
-
2010
- 2010-03-02 IL IL204264A patent/IL204264A/en not_active IP Right Cessation
- 2010-03-04 TN TNP2010000100A patent/TN2010000100A1/fr unknown
- 2010-03-29 ZA ZA2010/02206A patent/ZA201002206B/en unknown
- 2010-04-14 MA MA32775A patent/MA31779B1/fr unknown
- 2010-04-21 CO CO10046631A patent/CO6270223A2/es not_active Application Discontinuation
- 2010-04-21 CR CR11383A patent/CR11383A/es unknown
-
2011
- 2011-03-29 ZA ZA2011/02350A patent/ZA201102350B/en unknown
-
2012
- 2012-06-11 US US13/493,616 patent/US8853409B2/en not_active Expired - Fee Related
-
2014
- 2014-09-23 US US14/494,430 patent/US9079890B2/en not_active Expired - Fee Related
-
2015
- 2015-03-12 CR CR20150131A patent/CR20150131A/es unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1348370A (zh) * | 1999-04-15 | 2002-05-08 | 布里斯托尔-迈尔斯斯奎布公司 | 环状蛋白酪氨酸激酶抑制剂 |
| CN1390215A (zh) * | 1999-09-10 | 2003-01-08 | 麦克公司 | 酪氨酸激酶抑制剂 |
| WO2007026761A1 (ja) * | 2005-08-31 | 2007-03-08 | Astellas Pharma Inc. | チアゾール誘導体 |
| WO2007053345A1 (en) * | 2005-11-01 | 2007-05-10 | Array Biopharma Inc. | Glucokinase activators |
| WO2007117381A2 (en) * | 2006-03-24 | 2007-10-18 | Array Biopharma Inc. | 2 -aminopyridine analogs as glucokinase activators |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101566042B1 (ko) | 진성 당뇨병을 치료하기 위한 글루코키나제 활성화제로서의 피리딘-2-일-아미노-1,2,4-티아디아졸 유도체 | |
| JP6215315B2 (ja) | ピリジノンおよびピリダジノン誘導体 | |
| JP5450108B2 (ja) | グルコキナーゼ活性化剤としての2−アミノピリジン類似体 | |
| KR102019643B1 (ko) | 암 및 면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스 유도제로서의 8카바모일2(2,3이치환된 피리드6일)1,2,3,4테트라하이드로이소퀴놀린 유도체 | |
| US20250122221A1 (en) | Six-membered cyclothiazole compound and use thereof | |
| JP2010527911A5 (cg-RX-API-DMAC7.html) | ||
| TW201443051A (zh) | 二氫-吡咯并吡啶酮抑制劑 | |
| HK1216887A1 (zh) | 布鲁顿酪氨酸激酶的抑制剂 | |
| CN103380117A (zh) | 激酶的吡啶酰胺抑制剂 | |
| HK1230179A1 (en) | Pyridin-2-yl-amino-1,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus | |
| HK1183482A (en) | Pyridin-2-yl-amino-1,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus | |
| HK1145498B (en) | Pyridin-2 -yl-amino-i, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus | |
| HK1197821B (en) | Pyridin-2-yl-thiourea and pyridin-2-yl-amine derivatives as intermediates for the preparation of pyridin-2yl-amino-1,2,4-thiadiazole glucokinase activators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131218 Termination date: 20180915 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |